Multidrug Resistance in ESKAPE Bacteria and Pathogens

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 228

Special Issue Editor

Research in Drug Development, Faculté de Pharmacie, Université libre de Bruxelles (ULB), 1050 Brussels, Belgium
Interests: Mycobacterium; drug tolerance; vancomycin; dormancy; biofilm

Special Issue Information

Dear Colleagues,

It is well-established that the spread of microorganisms, especially in hospital, of antimicrobial-resistant ESKAPE bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) and other multi-drug-resistant microorganisms, such as Mycobacterium tuberculosis, is alarming. Surveillance and prophylactic measures to restrain the threat of these infections are based on and require global understanding of all factors influencing drug tolerance, microorganism persistence and drug resistance development in order to eventually develop the best adapted antimicrobial stewardship or to develop new efficient antimicrobial drug regimens. However, the questions remain: How can we address these questions in the best way? What can we learn from the adaptation of one type of bacteria? Could similar events take place with other microorganisms? Should we assess the fitness cost of drug resistance or tolerance when developing new drug regimens or new antibiotics? It may also be necessary to explore the existing public–private partnerships for drug discovery and development in TB control. Could large data sharing platforms (e.g., the Comprehensive Antibiotic Resistance Data (CARD) platform and the NCBI National Database of Antibiotic Resistant Organisms (NDARO)) facilitate data mining and assimilation to generate new hypotheses? We hope that this Special Issue will provide you with new opportunities to present your results, but also to share your opinions. This Issue aims to expand our understanding of antimicrobial bacteria mechanisms and possible means to target them.

Dr. Véronique Fontaine
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ESKAPE bacteria
  • multi-drug resistance
  • drug resistance
  • microorganisms
  • antimicrobial resistance
  • antibiotics

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop